International Multi-center Comparative Double-blind Randomized Clinical Trial of Efficacy and Safety of BCD-055 (JSC BIOCAD, Russia) and Remicade in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis

Trial Profile

International Multi-center Comparative Double-blind Randomized Clinical Trial of Efficacy and Safety of BCD-055 (JSC BIOCAD, Russia) and Remicade in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Infliximab (Primary) ; Folic acid; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms LIRA
  • Sponsors Biocad
  • Most Recent Events

    • 17 Jun 2017 Results of three clinical trials of infliximab biosimilar BCD-055 (ASART-1, ASART-2 and LIRA) including comparative data on pharmacokinetics (PK), efficacy and safety in a variety of patient populations, presented at the 18th Annual Congress of the European League Against Rheumatism.
    • 10 Jun 2017 Biomarkers information updated
    • 12 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top